Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of F9. The page also collects GeneMedi's different modalities and formats products for F9 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the F9 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Sep 2015]

Target IDGM-T83369
Target NameF9
Gene ID2158
Gene Official NameF9
Gene AliasF9 p22, FIX, HEMB, P19, PTC, THPH8
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index


Pre-made F9-specific INN-index biosimilar (antibody&conjugates)-albutrepenonacog alfa, nonacog gamma, dalcinonacog alfa, Emicizumab, eftrenonacog alfa

Anti-F9 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-INN-726Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8albutrepenonacog alfaF9Fusion ProteinINN mab
GMP-Bios-INN-929Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8nonacog gammaF9Recombinant ProteinINN mab
GMP-Bios-INN-792Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8dalcinonacog alfaF9Recombinant ProteinINN mab
GMP-Bios-ab-177Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibodyEmicizumabF9;F10Bispecific mAbINN mab
GMP-Bios-INN-830Pre-Made Eftrenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8eftrenonacog alfaF9Fusion ProteinINN mab



Pre-made anti-F9 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-F9 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-F9 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T83369-AbAnti-F9 monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×